AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03212365 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fixed dose
Description: Participants will receive 40 mg enoxaparin twice daily
Study NCT03212365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variable dose
Description: Participants will receive 0.5mg/kg enoxaparin twice daily
Study NCT00005982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study NCT00005982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00165152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
Study NCT00165152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Informed Consent Counseling
Description: Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
Study NCT03050294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Phone calls twice daily
Study NCT03050294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Description: Desoximetasone 0.25% spray applied twice daily
Study NCT03050294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desoximetasone 0.25% spray
Description: Desoximetasone 0.25% spray applied twice daily
Study NCT06409403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clinical application of robotic technique
Description: effect of various surgical technique on clinical efficacy of TME
Study NCT03462069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02721199 — intervention group
Intervention type: OTHER
Intervention: Neural Respiratory Drive Automated EMGpara assessment
Description: Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
Study NCT03462069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03462069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT03462069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT00478374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg bid
Study NCT00478374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation with doxorubicin
Description: Transarterial chemoembolisation (TACE)
Study NCT04186481 — intervention group
Intervention type: DEVICE
Intervention: MINITAC Ti 2.0 suture anchor
Description: The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
Study NCT04658173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam-alfentanil combination
Description: Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
Study NCT04658173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-alfentanil combination
Description: Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
Study NCT01231230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: 220- mcg once
Study NCT01231230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo inhalation
Description: placebo inhalation once
Study NCT01231230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: 50 mcg salmeterol once
Study NCT01231230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol
Description: inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
Study NCT00190515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU+l-leucovorin
Description: 5FU+l-leucovorin
Study NCT00190515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT+Leucovorin
Description: UFT+Leucovorin
Study NCT00495131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a plus ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
Study NCT02046317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Femoral Nerve Block for isolated femur fractures
Study NCT02046317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Femoral Nerve Block for isolated femur fractures
Study NCT02046317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echogenic needle
Description: The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
Study NCT01091181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysterotomy at cesarean
Description: incision to open the uterus at cesarean.
Study NCT01650337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Smartphone application to help monitor caloric intake and expenditure
Study NCT04150835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Study NCT04150835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xingnaojing placebo injection
Description: Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Study NCT04150835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.
Study NCT04150835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.
Study NCT02477826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02477826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02477826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01323543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elaspine™
Description: Implantation of device
Study NCT02477826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02477826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02477826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02477826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT03347838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT04057833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC
Description: Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
Study NCT02046317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care needle
Description: The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
Study NCT03796221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting videos
Description: Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
Study NCT01737268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral tablet
Study NCT05547659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
Study NCT05547659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1 G Oral Tablet
Description: Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
Study NCT05547659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 400Mg Oral Capsule
Description: Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
Study NCT01339221 — intervention group
Intervention type: PROCEDURE
Intervention: Stool samples
Description: Stool samples collected and checked for the presence of rotavirus
Study NCT01084421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based parent-adolescent HIV communication
Description: The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
Study NCT03697460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424
Description: INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
Study NCT00665561 — intervention group
Intervention type: DRUG
Intervention: Maraviroc along with an optimized background antiretroviral drug regimen
Description: Maraviroc prescribed per approved local label.
Study NCT00665561 — intervention group
Intervention type: DRUG
Intervention: Optimized background antiretroviral drug regimen without maraviroc
Description: Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
Study NCT00813488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet
Description: FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician.
Study NCT00813488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release oxycodone
Description: Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules).
Study NCT01273090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imetelstat sodium
Study NCT01273090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01273090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00425542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient care (vs traditional inpatient care)
Description: Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
Study NCT03677375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00026
Description: Noninvasive pulse oximeter sensor
Study NCT00901056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: Energy Density - 0.02 - 0.15 mJ/mm2
Study NCT04145102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hesperidine
Description: used for antibacterial and reminerlization assesment
Study NCT04145102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propolis
Description: used for antibacterial and reminerlization assesment
Study NCT04145102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: used for antibacterial and reminerlization assesment
Study NCT03796221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pediatric obesity treatment
Description: Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
Study NCT03796221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard pediatric obesity treatment
Description: Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
Study NCT04439357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT03829683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 200mg/kg/24hours
Study NCT02046317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
Study NCT02046317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
Study NCT04364763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-9 (90 mg)
Description: Subjects will receive a single dose and study duration will be approximately 60 days per subject.
Study NCT04364763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride (normal saline)
Description: Subjects will receive a single dose and study duration will be approximately 60 days per subject.
Study NCT04609397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tables 60mg bid p.o;
Study NCT04609397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: Hemay005 tables 60mg bid p.o;
Study NCT04609397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tables 45mg bid p.o
Study NCT04609397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: Hemay005 tables 45mg bid p.o
Study NCT04609397 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to Hemay005 tables bid p.o
Study NCT04498676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CB-0002B
Description: CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
Study NCT02455947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Description: During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
Study NCT04432077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)
Description: DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
Study NCT00748137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ezy-BICC dose calculation card
Description: small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
Study NCT00748137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed dose
Description: Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
Study NCT01176981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Methotrexate
Description: Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days).
Study NCT01316432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenderitide
Description: Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
Study NCT01316432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a 24-hour SQ infusion
Study NCT03969108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
Study NCT00834314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-Pack-technique for temporary abdominal closure
Description: Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations).
Study NCT00834314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal-dressing-technique for temporary abdominal closure
Description: Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
Study NCT04361838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prayer
Description: receive prayers daily while in ICU
Study NCT00494741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.